ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE:

28.07.2021

COVID absence and driver shortages continue across the country and, as a business, we are working hard to mitigate the situation.

 

COVID absence

 

England and Wales saw in excess of 600,000 Test and Trace app alerts last week and the isolations caused by these ‘pings’ have been leading to increased absences across our network. We are glad to say that the Government has now added Alliance Healthcare UK to the critical, front line workers list of those who are exempt from isolation due to Test and Trace contact. This came into effect on Friday 23 July and will now help to reduce our absence numbers.

 

At Alliance Healthcare we have worked on our own absence model, based on Government modelling for infection rates. We are proactively managing the situation on a daily basis and have plans in place to mitigate issues caused by potentially escalating absence levels.

 

We have made the decision to maintain COVID secure measures across all of our sites for the foreseeable future, even as many restrictions are legally being lifted. This includes; increased cleaning, social distancing and mask wearing to continue out service to the NHS and community pharmacy, while ensuring the safety of our teams.

 

Driver shortages

 

In regard to driver shortages, we have also launched an ongoing recruitment drive to encourage drivers to join our business. This went live from 16 July and we would be grateful if customers, colleagues and friends can refer any individuals to us if they could be suitable for a role – you can find details on our LinkedIn channel here.

 

We are proud to have kept up our twice daily deliveries (Mon-Fri) through waves one and two of the pandemic and this has given us expert experience of how to invoke business continuity plans. However, we still have some challenges to overcome to ensure that we maintain a stable service. You, our customers, remain our top priority and we thank you for your continued patience and support whilst we work through rectifying issues, where they exist in the network.

The UK patient is at the heart of everything we do, and we appreciate your continued dedication.

 

We will continue to keep you updated on the situation as it evolves.

SUB-TYPE:

27.07.2021

Alliance Healthcare Service Centre Opens COVID-19 Vaccination Clinic

Thanks to a joint initiative between Wigan Council and the NHS Greater Manchester Clinical Commissioning Group (CCG), some of our team members based at Leigh Service Centre received their first COVID-19 vaccination whilst at work.

 

Four health professionals attended the one day clinic to administer the Pfizer vaccine to 30 team members, who were delighted that they were able to receive their first jab and that it was available to them at their place of work. 

 

Fran Gray, Warehouse Operations Manager, who led the activity and ensured the smooth running on the day said: “This has been hugely beneficial for our team members that do not have their own transportation, and they have been supported by people they know.”

 

Commenting on the vaccine clinic Zak Patel, Leigh Service Centre Manager, said: “It’s been fantastic that we have been able to offer the vaccination to some of our team through this one day event.

 

“Earlier in the year we worked with the council to offer COVID-19 testing to our team and, like the vaccine, it was hugely appreciated.

 

“We have a good relationship with the local council and we’re happy to work with them on initiatives such as this. I’m also a member of the Greater Manchester Chamber of Commerce which has helped to strengthen our relationships with businesses in the area and Wigan Council.”

 

Following the success of the vaccine clinic, the council is now looking to roll out the Leigh model to other businesses in the area.

 

site

 

SUB-TYPE:

09.07.2021

Alliance Healthcare Team Member Along with Owner of Peel Green Pharmacy Recognised with the Mayor of Preston's Coronavirus Community Hero Award

 

We are delighted that Zak Patel, our Leigh Service Centre Manager, and Nasim Patel, owner of Peel Green Pharmacy, have received this special award, along with associates, for establishing Fulwood Foodbank, to support Preston residents in need through the pandemic.

 

On a weekly basis the group delivered food parcels to families that had been referred to them by Preston City Council, schools and colleges, and local charities.  Supermarkets in the area donated essential food items, as well as nappies and formula, while other local businesses and residents made generous financial contributions – some weeks it was in excess of £7,000!

 

At the height of the pandemic, they were supporting 2,000 families with three meals a day, seven days a week – that’s a staggering 42,000 meals a week!

 

Commenting on the award, Managing Director Julian Mount says: “It is fantastic recognition that Zak Patel, our Leigh Service Centre Manager, has been formally recognised by the Mayor of Preston for his local community support work in the height of the pandemic.  Zak is a true example to us all in selflessly putting his community first.  I want to thank Zak for being such a great example to us all.”

 

Zak Patel says: “I’m proud of how we have been able to help our community and it’s an honour to be recognised. The pandemic has quashed the myth that food banks are just for those sleeping rough as people with homes and jobs have been reliant on them through COVID. It’s heartening to see what can be achieved when we work together.”

 

Nasim Patel, Peel Green Pharmacy, says: “As a pharmacist I could see that patients were experiencing hardship and struggling before the pandemic. I knew that COVID would amplify the situation and wanted to be able to support the most vulnerable in our community.”

 

Alliance Healthcare is proud of the vital role its team members play to support the NHS, independent pharmacy and the communities it serves.

 

Zak Patel
Zak Patel, Leigh Service Centre Manager at Fulwood Foodbank

 

SUB-TYPE:

Alphega Pharmacy Proudly Champions TEAMtime for its members with Pharmacist Support

 

Alphega Pharmacy continues its commitment to help the wellbeing of its pharmacy members across the UK, as proud sponsors of TEAMtime with Pharmacist Support – running from Monday 5 July to Friday 9 July inclusive.

 

Following on from the successful partnership with Pharmacist Support in 2020, on the #ACTnow wellbeing campaign, Alphega Pharmacy is teaming up with Pharmacist Support once again to run a new campaign dedicated for its members. The campaign, appropriately called – TEAMtime, will encourage Alphega Pharmacy members to spend time with their team, putting their team members wellbeing first and having a well-earned break.

 

“We recognise that this has been an especially challenging 18 months for our pharmacy members, and here at Alphega Pharmacy we wanted to do something to help” commented Raj Nutan, Head of Alphega Pharmacy UK.

 

“Pharmacy teams spend much of their day focusing on others and can often find it difficult to spend the time to focus on themselves. But this is so important. During TEAMtime we want to help our members prioritise themselves and their teams. By working with Pharmacist Support and encouraging our members to make time for TEAMtime, we hope it will kick start an Alphega Pharmacy team wellbeing routine”

 

Across the week, newly trained Alphega „Wellbeing Champions‟ and charity ambassadors will be visiting members and encouraging them to participate in a number of activities. The campaign is focusing on four key areas that will kick start the campaign week, these include:

 

- TEAMtime Tea Break - Set aside some time at the beginning or end of the day with a cup of tea and biscuit, to just connect with your team and chat!


-TEAMtime Positivity Board - Create a board with post-it notes, to share the small positiveinteractions you have with colleagues and patients, to help you celebrate and appreciate thesmaller things each day


-TEAMtime Active Challenge – Being active is good for your lungs, heart, and head, so challengeyourself and your team to get out and about during lunch breaks or even before or after work.


-TEAMtime Mindfulness – Download a mindfulness app (e.g. Calm or Headspace) to help supportyou to manage day-to-day stresses and strains or simply complete a daily crossword or sudokuduring your lunch break to give your mind a break.


Raj also highlighted what mental health support Alphega Pharmacy are providing to its colleagues: ”As a business, we believe in not only supporting our members mental health but also supporting each other. We have committed to providing metal health first aider training to our Alphega Pharmacy Business Mentor team by the end of the year, with over 50% of the team already having completed the training so far.”

 

Danielle Hunt, Chief Executive of Pharmacist Support said: “We‟re absolutely delighted to be working with Alphega Pharmacy once again. We have seen through our research over the past couple of years, increasingly high levels of stress and burnout across the profession. We‟re keen to work with organisations across the sector to address these issues and as an independent charity, feel we are well placed to provide this support. Through our partnership with Alphega Pharmacy, we want to help pharmacy teams establish simple routines that improve mental wellbeing for individuals and organisations. We want to showcase how setting aside a small amount of time every day for wellbeing can improve mood, relationships and productivity.”


To find out more about how Alphega Pharmacy can help independent pharmacy businesses, please call: 0203 044 8969 or email: membersupport@alphega-pharmacy.co.uk

SUB-TYPE:

Alphega Pharmacy proudly champions TEAMtime for its members with Pharmacist Support

 

Alphega Pharmacy continues its commitment to help the wellbeing of its pharmacy members across the UK, as proud sponsors of TEAMtime with Pharmacist Support – running from Monday 5 July to Friday 9 July inclusive.

 

Following on from the successful partnership with Pharmacist Support in 2020, on the #ACTnow wellbeing campaign, Alphega Pharmacy is teaming up with Pharmacist Support once again to run a new campaign dedicated for its members. The campaign, appropriately called – TEAMtime, will encourage Alphega Pharmacy members to spend time with their team, putting their team members wellbeing first and having a well-earned break.

 

“We recognise that this has been an especially challenging 18 months for our pharmacy members, and here at Alphega Pharmacy we wanted to do something to help” commented Raj Nutan, Head of Alphega Pharmacy UK.

 

“Pharmacy teams spend much of their day focusing on others and can often find it difficult to spend the time to focus on themselves. But this is so important. During TEAMtime we want to help our members prioritise themselves and their teams. By working with Pharmacist Support and encouraging our members to make time for TEAMtime, we hope it will kick start an Alphega Pharmacy team wellbeing routine”

 

Across the week, newly trained Alphega „Wellbeing Champions‟ and charity ambassadors will be visiting members and encouraging them to participate in a number of activities. The campaign is focusing on four key areas that will kick start the campaign week, these include:

 

- TEAMtime Tea Break - Set aside some time at the beginning or end of the day with a cup of tea and biscuit, to just connect with your team and chat!


-TEAMtime Positivity Board - Create a board with post-it notes, to share the small positiveinteractions you have with colleagues and patients, to help you celebrate and appreciate thesmaller things each day


-TEAMtime Active Challenge – Being active is good for your lungs, heart, and head, so challengeyourself and your team to get out and about during lunch breaks or even before or after work.


-TEAMtime Mindfulness – Download a mindfulness app (e.g. Calm or Headspace) to help supportyou to manage day-to-day stresses and strains or simply complete a daily crossword or sudokuduring your lunch break to give your mind a break.


Raj also highlighted what mental health support Alphega Pharmacy are providing to its colleagues: ”As a business, we believe in not only supporting our members mental health but also supporting each other. We have committed to providing metal health first aider training to our Alphega Pharmacy Business Mentor team by the end of the year, with over 50% of the team already having completed the training so far.”

 

Danielle Hunt, Chief Executive of Pharmacist Support said: “We‟re absolutely delighted to be working with Alphega Pharmacy once again. We have seen through our research over the past couple of years, increasingly high levels of stress and burnout across the profession. We‟re keen to work with organisations across the sector to address these issues and as an independent charity, feel we are well placed to provide this support. Through our partnership with Alphega Pharmacy, we want to help pharmacy teams establish simple routines that improve mental wellbeing for individuals and organisations. We want to showcase how setting aside a small amount of time every day for wellbeing can improve mood, relationships and productivity.”


To find out more about how Alphega Pharmacy can help independent pharmacy businesses, please call: 0203 044 8969 or email: membersupport@alphega-pharmacy.co.uk

SUB-TYPE:

29.06.2021

Pharmacy Recognised for COVID-19 Efforts as Alliance Healthcare Calls for Continued Expansion of Community Pharmacy Following HM Government Funding Announcement

 

29 June 2021


Pharmacies across England will be able to claim for COVID-19 costs in line with the recent announcement by PSNC with the HM Government funding. Alliance Healthcare and Alphega Pharmacy is pleased that community pharmacy is now recognised for its instrumental role in the fight against COVID-19 and the success of the COVID-19 vaccination success.


Speaking on the decision, Julian Mount, Managing Director, Alliance Healthcare said: “Since the start of the pandemic, pharmacy customers and patients have recognised the dedication and commitment of pharmacy teams, as the frontline for the NHS for over 15 months. It is great news that now the Department for Health and Social Care is seeing this value too, and we appreciate the hard work from the PSNC and government to support community pharmacy, and we hope to see it go even further.


“In addition to this important step, we must continue to stay focused on recognising the essential role community pharmacists have in improving the health of patients across the UK and create a reimbursement structure that reflects their positive impact.


“The next stage is how we look at the further integration of community pharmacy in England into the primary healthcare team – with autumn on the horizon, winter aliments, flu vaccinations and COVID-19 boosters – we need to ensure the treasury recognise the contribution of pharmacy. Then longer term pharmacy has a key role in helping address backlogs in health, mental health and long-term conditions – and this must be addressed and not forgotten by the relevant stakeholders.”


Raj Nutan, Head of Alphega Pharmacy UK comments: “Notwithstanding the issues surrounding the advance payments, overall, we recognise the work PSNC has done in getting a decision and welcome at long last there is a recognition by the government of the costs pharmacies have had during this difficult COVID-19 period – with community pharmacy going above and beyond, as always, for the UK patients.


The Alphega Pharmacy team will be monitoring and awaiting the detailed guidance from the Drug Tariff with further input from PSNC. In the meantime, we stand ready to support all of our pharmacists any way we can to ensure all Alphega Pharmacy members can appropriately, accurately and effectively claim their costs within a timely window.”

 

Alphega Pharmacy Sneeze Screens - AH delivery driver - 2021

 

SUB-TYPE:

23.06.2021

Alloga UK and Alliance Healthcare UK are Integral to the Delivery of COVID-19 Vaccinations

 

Alloga UK and Alliance Healthcare UK are proud to announce that they have played an instrumental role in supporting the NHS with the delivery of COVID-19 vaccines across England. To date, Alloga UK - with the support from colleagues across Alliance Healthcare – has delivered 24.6 million doses of COVID-19 vaccine. The teams have delivered vaccines to approximately 1,490 sites of care, including hospitals, major vaccination centres, care homes and prisons since December 2020, with deliveries taking place up to seven days a week.

 

Under the leadership of Chris Williams, Managing Director, Alloga UK, a dedicated team ensured that all necessary processes and preparations were accommodated to distribute vaccines to approximately 50% of England. This involved an area of the Alloga facility being cordoned off to keep the operation classified. The site was also visited numerous times by Government appointed security agencies to ensure safety and security of the vaccines’ storage. 

 

Alloga working group

 

Julian Mount, Managing Director, Alliance Healthcare UK said: “I am so proud that our business and our colleagues are playing such a key part in the lifesaving effort of COVID-19 vaccine distribution. Team members from multiple departments across the business, have all come together to support this national effort. I want to personally thank each and every one who has been involved. It is a fantastic joint endeavour, and it is just one more example of how Alliance Healthcare and Alloga are working together to support the NHS and patients across the UK.”

 

Alloga Infographic

Chris Williams comments: “Alloga UK is delighted to be playing a key part in the distribution of COVID-19 vaccines across England. Our unrivalled experience in vaccine distribution has informed our approach and allowed us to work at pace with NHSE in designing and implementing this very complex supply chain within such a short period of time. This implementation has been far from easy, but our professional teams coupled with a can-do mentality has allowed us to overcome many logistics challenges and implement an excellent solution. The teams across NHSE, Alloga UK and Alliance Healthcare UK should be justifiably proud of their collective achievement.”

 

* As at 21 June, 2021. 

 

Alloga team member with chilled vaccine

 

­­­­­­­­­­­­­­

SUB-TYPE:

Mike Smith, Alliance Healthcare UK announces retirement

Mike Smith, non-executive advisor, Alliance Healthcare UK has announced his retirement after 30 years with the company. In announcing his retirement to team members on Tuesday 22 June, Mike said: “The time has come for me to retire and it has been a privilege to meet and work with truly incredible people at Alliance Healthcare. I have long been an avid ambassador for community pharmacy and our industry's remarkable dedication in the fight against the COVID-19 pandemic has made me very proud. To my friends and peers I wish you all a very healthy and happy future.”

SUB-TYPE:

16.06.2021

Alliance Healthcare Supports Vitamin Angels UK By Taking On A Colleague Cycle Challenge

Alliance Healthcare Supports Vitamin Angels UK By Taking On A Colleague Cycle Challenge

Alliance Healthcare has been supporting Vitamin Angels and Vitamin Angels UK for several years. In recent months, fundraising has been difficult due to COVID-19 restrictions. However, some Alliance Healthcare team members were keen to get out to do their bit to raise vital funds for this worthwhile charity.

 

In 2019 Alliance Healthcare held the inaugural cycle event and this year, seven cyclists and one support driver have come together to take on another cycle challenge. This one covered over 300 miles in four days. The challenge began at Alliance Healthcare’s Coatbridge service centre, just east of Glasgow and finished at the South Normanton site in Derbyshire.

 

The cyclists come from various teams across the business including transport, procurement, health and safety and service centre management. Matt Addison, Director of Operations, Alliance Healthcare is one of the riders and also the instigator of the fundraising challenge. Matt said about the event: “Taking on this challenge, down from Scotland, through the Lake District and over the Pennines, was an epic undertaking. However, I felt it was important for Alliance Healthcare to continue our support of Vitamin Angels UK. They are an amazing charity and the work they do to help at-risk populations in the UK and around the world deserves our support. I’m proud to say that to date we have raised over £25,000 from this event – but we still want more!”

 

Roma Mirutenko, Account Manager, Vitamin Angels UK said: “We truly thank Alliance Healthcare so much for their commitment to Vitamin Angels UK and everything we do together! Their continued support and drive to go the distance means the world to all of us at Vitamin Angels UK and Vitamin Angels Global! Thank you for helping us improve nutrition for children in the UK and beyond!”

 

Alliance Healthcare and Vitamin Angels UK send big thanks to their most generous sponsors this year: LCM Group, Jungheinrich UK Ltd, SMI, Driver Hire Nationwide and Lexmark.

AH Cycle - Setting off from Coatbridge

Alliance Healthcare Cycle - setting off from Coatbridge with a bagpiper

 

AH Cycle - with Vitamin Angels mascot

Alliance Healthcare Cycle Team  with Vitamin Angels Mascot at end of challenge

 

About Vitamin Angels UK:

 

Vitamin Angels UK work towards the relief of sickness and preservation of health by providing or assisting in the provision of nutrients and services for the benefit of mothers and children and to work to end malnutrition and its consequences among at-risk, hard-to-reach populations (e.g., defined generally as individuals lost to national health services), focusing on young children under five years of age, and women of reproductive age, including especially pregnant women and their unborn child and new mothers and to advance the education of the general public in all areas relating to healthcare for mothers and children. To learn more visit: www.vitaminangels.org.uk

SUB-TYPE:

02.06.2021

AmerisourceBergen completes acquisition of Alliance Healthcare businesses

Acquisition Advances Role as a Key Pillar of Pharmaceutical Innovation and Access Adjusted Diluted EPS Guidance Range Raised to $8.90 to $9.10 for Fiscal 2021

 

CONSHOHOCKEN, PA, JUNE 2, 2021 — AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of the majority of Walgreens Boots Alliance’s Alliance Healthcare businesses for $6.275 billion in cash, subject to a customary working capital and net debt adjustment, and 2 million shares of AmerisourceBergen common stock.

 

“We are excited to complete the acquisition and extend a warm welcome to the talented team at Alliance Healthcare,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “The acquisition of Alliance Healthcare expands our reach and solutions in pharmaceutical distribution and adds to AmerisourceBergen’s breadth and depth of global manufacturer services. With Alliance Healthcare, we will advance our ability to provide innovative and global healthcare solutions and further our purpose of being united in our responsibility to create healthier futures.”

 

“This transaction provides great benefit for both companies and is a logical step following the continued success of our long-term strategic relationship,” said Ornella Barra, Chief Operating Officer, International, Walgreens Boots Alliance, Inc. “The Alliance Healthcare teams are joining a global pharmaceutical distribution leader and trusted partner in AmerisourceBergen, and we look forward to continuing to work together as strategic partners.

 

AmerisourceBergen and Walgreens Boots Alliance will also execute on the expansion and extension of commercial agreements in order to drive incremental growth and synergies.

 

Fiscal Year 2021 Expectations

 

The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated.

 

Fiscal Year 2021 Expectations on an Adjusted (non-GAAP) Basis

 

AmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the expected contribution from the closing of the Alliance Healthcare acquisition and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the Company delivered at closing of the transaction. The Company now expects:

 

• Revenue of at least $210 billion, up from revenue growth in the high-single digit percent range; and

• Adjusted diluted earnings per share (EPS) to be in the range of $8.90 to $9.10, raised from the previous range of $8.45 to $8.60.

 

 

Additional expectations now include:

 

• Weighted average shares of at least 208 million, raised from the previous expectation of between 207 million and 208 million for the fiscal year.

 

The Company continues to have strong performance across its businesses and expects to update the rest of its previously announced fiscal 2021 financial guidance when it reports results for the third quarter of fiscal 2021. Alliance Healthcare’s results will be reported in Other for the remainder of fiscal year 2021.

 

Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures below.

 

About AmerisourceBergen

 

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our 3 responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

 

Supplemental Information Regarding Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses adjusted diluted EPS. Adjusted diluted EPS should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. Adjusted diluted EPS may vary from, and may not be comparable to, similarly titled measures by other companies.

 

Adjusted diluted EPS is presented because management uses this non-GAAP financial measure to evaluate the Company’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, the Company believes that the presentation of this non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors.

 

The non-GAAP fiscal year 2021 guidance for adjusted diluted EPS excludes significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring or non-cash in nature. The Company does not provide forward looking guidance on a GAAP basis for such metric because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated.

 

For fiscal year 2021, adjusted diluted EPS excludes the per share impact of certain adjustments including gain from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization; and employee severance, litigation, and other; in each case net of the tax effect calculated using the applicable effective tax rate for those items. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.

 

AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements

 

Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Such forward-looking statements may include, without limitation, statements about the Alliance Healthcare acquisition, the benefits of the Alliance Healthcare acquisition, future opportunities for AmerisourceBergen and any other statements regarding AmerisourceBergen’s future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward looking statements.

 

These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove 4 incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Company’s or Alliance Healthcare’s failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational 5 factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forwardlooking statements are set forth (i) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.